Every material Form 8-K ROCKWELL MEDICAL, INC. has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On November 2, 2026, Rockwell Medical agreed to acquire Vantive's in-center hemodialysis business in 35 jurisdictions, with a $125 million base price financed mainly by seller loans and a convertible note from Vantive affiliates. The company also withdrew its previously issued 2026 guidance, citing expected transaction and financing expenses. Shareholders face substantially higher debt, potential dilution from the convertible note, and closing that is expected in mid-2027 and subject to regulatory approvals.
Equity and Asset Purchase Agreement with Vantive Limited dated November 2, 2026, covering the in-center hemodialysis business in 35 jurisdictions
Base purchase price of $125 million, funded by two $50 million term loans and a $25 million convertible note from Vantive affiliates, plus up to $45 million in earnout payments
2026 guidance for net sales, gross margin, adjusted EBITDA and operating cash flow withdrawn
Expected closing in mid-2027, subject to regulatory approvals; combined business projected annual revenue of $400 million to $450 million
Rockwell Medical furnished an updated corporate presentation to investors on August 13, 2026, as Exhibit 99.1 to a Form 8-K. The filing contains no financial results, guidance, or other quantitative figures, and the company states the information is not deemed filed under Section 18 of the Exchange Act.
Updated corporate presentation made available on August 13, 2026, furnished as Exhibit 99.1
Filed under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits)
Filing signed by CEO Mark Strobeck; signature block is dated May 7, 2026, which differs from the August 13, 2026 filing date
Rockwell Medical reported second-quarter 2026 results on August 13, 2026. Net sales rose 11% to $17.8 million from $16.1 million a year earlier, and the net loss narrowed to $1.2 million from $1.5 million. The company reiterated its full-year 2026 guidance, including net sales of $70.0 million to $75.0 million.
Q2 2026 net sales were $17.8 million, up 11% from $16.1 million in Q2 2025.
Net loss for the quarter was $1.2 million, or $(0.34) per share, versus a net loss of $1.5 million, or $(0.48) per share, a year earlier.
Gross margin was 18%, up from 16% a year earlier; cash and investments were $24.8 million at June 30, 2026.
2026 guidance reiterated: net sales $70.0 million to $75.0 million, gross margin 18% to 22%, Adjusted EBITDA $1.0 million to $2.0 million, and positive operating cash flow.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ROCKWELL MEDICAL, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →